Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Biotechnology investors often compare the steady cash flows of established giants with the explosive potential of specialized innovators. Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing scale against high-margin specialization.

Amgen operates as a global pharmaceutical titan with a massive portfolio spanning multiple therapeutic areas. Vertex focuses on transformative therapies for rare diseases, historically dominating the cystic fibrosis market. Comparing these two involves choosing between a diversified income-generating giant and a focused biotech specialist with an expanding pipeline.

The case for Amgen

Amgen discovers and develops medicines for serious diseases across oncology, inflammation, and rare disease categories. The company distributes its products globally, relying heavily on its primary partners McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). These three distributors accounted for nearly 77% of worldwide gross revenues in 2025, which represents a significant customer concentration risk.

In FY 2025, revenue reached nearly $36.7 billion, representing growth of approximately 9.9% compared to the previous year. This performance translated into net income of roughly $7.7 billion for the period. Amgen reported a healthy net margin of approximately 21%.

As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 6.3x. This metric measures total debt against shareholder equity, with a higher number suggesting more reliance on borrowing. The current ratio is roughly 1.1x, and the company generated nearly $8.1 billion in free cash flow, representing cash left after capital expenditures.

The case for Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on transformative medicines for life-threatening diseases, maintaining a dominant global franchise in cystic fibrosis therapies. According to its latest annual report, filed for the 2025 period, the company reaches patients through specialized distributors and pharmacy benefit managers. Vertex also collaborates with partners like Moderna (NASDAQ:MRNA) and has secured payer agreements covering over 275 million lives.

In FY 2025, revenue reached nearly $12.1 billion, which is a growth rate of approximately 9.6% year over year. The company reported net income of roughly $4.0 billion, a significant recovery from the net loss recorded in the prior fiscal year. Vertex also maintained an impressive net margin of close to 32.7%, showing the percentage of revenue remaining as profit after all expenses.

As of the December 2025 balance sheet, the debt-to-equity ratio is approximately 0.2x. This indicates that total debt is very low relative to shareholder equity, providing the company with significant financial flexibility. The current ratio stands at roughly 2.9x, and the company produced nearly $3.2 billion in free cash flow after accounting for capital investments.

Risk profile comparison

Amgen faces significant pricing pressure from government programs like Medicare and state-level prescription drug boards. Revenue stability is further threatened by competition from biosimilar versions of major products like Prolia. Additionally, the company is managing ongoing tax litigation with the IRS and must navigate potential supply chain disruptions at its concentrated manufacturing sites.

Vertex is highly dependent on its cystic fibrosis medications, which account for the vast majority of its current revenue. The company faces intense competition and pricing pressure from federal cost-containment initiatives and potential rivals like AbbVie (NYSE:ABBV). Expanding into new therapeutic areas like gene therapy involves high development costs, regulatory uncertainty, and complex manufacturing hurdles.

Valuation comparison

Amgen appears to be the more value-oriented choice based on its lower multiples, while Vertex carries a premium price reflecting its higher net margin.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Vertex Pharmaceuticals. Few biotech companies at this scale are growing as profitably across as many disease areas simultaneously. Its cystic fibrosis drugs now reach the vast majority of patients living with the disease, a commercial and scientific achievement that took years to build and would be nearly impossible for a competitor to replicate. A new pain drug is gaining commercial traction, and a recently completed acquisition adds a kidney disease drug awaiting an imminent FDA approval decision. The balance sheet is flush with cash, and management raised its full-year outlook.

Amgen deserves credit for running one of the most dependable businesses in biotech. Multiple brands are growing at a double-digit rate, the full-year outlook has been raised, and the dividend keeps growing year after year. For investors who prioritize steady income alongside growth, it is a strong choice.

But Vertex is growing faster, expanding into more disease areas, and doing it with operating margins that most pharmaceutical companies would envy. The pipeline depth here is unusual and keeps getting broader. Amgen is the steadier ride, but Vertex is the one that keeps raising the ceiling on what the business can become.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, Moderna, and Vertex Pharmaceuticals. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.